Because benzodiazepines (BZ) and other anxiolytics are among the mode widely prescribed of all medications, anxiolytic misuse, abuse, and physiological dependence have been of increasing concern. This project will use drug discrimination procedures in laboratory animals to provide data relevant to issues of vulnerability to sedative/anxiolytic drug abuse and to the correspondence between molecular mechanisms of action and stimulus effects of anxiolytics. Drug discrimination procedures are useful because they can provide highly selective behavioral measures of CNS activity which may be analogous to human subjective drug effects. One objective is to explore the possible interrelationships between the discriminative stimulus and reinforcing effects of drugs by investigating (1) the effects of a history or drug self-administration on subsequent drug stimulus generalization, (2) the effects of specific drug discrimination training on subsequent drug self-administration and (3) drug discriminative stimulus effects in the context of ongoing self- administration. A second objective, particularly important because of increasing applications of the drug discrimination procedure in preclinical screening of anxiolytics, is to study the conditions under which the sedative/anxiolytic generalization profile broadens or narrows. One experiment involves appetitive and aversive training conditions, and another involves increasing the specificity of generalization test results by training a discrimination between sedative/anxiolytic drugs that otherwise show overlapping generalization profiles. A third major objective is to investigate the correspondence between molecular mechanisms of action of anxiolytics and their discriminative stimulus effects. One experiment will explore central mediation of the discriminative stimulus effects of BZ-receptor ligands by comparing results of centrally versus systemically administered compounds. Another experiment investigates the degree to which specificity of activity of a drug with respect to neurotransmitter systems implicated in the generation and amelioration of anxiety corresponds with its generalization profile in the drug discrimination paradigm. A fourth objective is to investigate the influence of chronic BZ administration on stimulus properties of BZ receptor ligand. One experiment will use a high-versus low- dose BZ training condition to determine whether BZ tolerance is reflected in lever choice during chronic drug administration. Another experiment will study whether qualitative and/or quantitative changes in discriminative stimulus effects of BZ receptor ligands (agonists, antagonists, and inverse agonists) under lorazepam and Beta-carboline training conditions occur as a function of BZ tolerance and dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA004133-04
Application #
3209328
Study Section
(SRCD)
Project Start
1986-04-01
Project End
1992-03-31
Budget Start
1989-04-01
Budget End
1990-03-31
Support Year
4
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Ator, Nancy A; Atack, John R; Hargreaves, Richard J et al. (2010) Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes. J Pharmacol Exp Ther 332:4-16
Kohut, Stephen J; Ator, Nancy A (2008) Novel discriminative stimulus effects of TPA023B, subtype-selective gamma-aminobutyric-acid(A)/benzodiazepine modulator: comparisons with zolpidem, lorazepam, and TPA023. Pharmacol Biochem Behav 90:65-73
Weed, Michael R; Wilcox, Kristin M; Ator, Nancy A et al. (2008) Consistent, high-level ethanol consumption in pig-tailed macaques via a multiple-session, limited-intake, oral self-dosing procedure. Alcohol Clin Exp Res 32:942-51
Ator, Nancy A (2005) Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr 10:31-9
Ator, Nancy A; Griffiths, Roland R; Weerts, Elise M (2005) Self-injection of flunitrazepam alone and in the context of methadone maintenance in baboons. Drug Alcohol Depend 78:113-23
Griffiths, Roland R; Bigelow, George E; Ator, Nancy A (2003) Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 70:S41-54
Ator, Nancy A (2003) Selectivity in generalization to GABAergic drugs in midazolam-trained baboons. Pharmacol Biochem Behav 75:435-45
Ator, Nancy A; Griffiths, Roland R (2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70:S55-72
Ator, Nancy A (2002) Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons. Psychopharmacology (Berl) 163:477-87
Kaminski, B J; Ator, N A (2001) Behavioral and pharmacological variables affecting risky choice in rats. J Exp Anal Behav 75:275-97

Showing the most recent 10 out of 28 publications